Jens Nagel

USPTO Granted Patents = 17 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 19(Granted Patents)

Location History:

Blankensee, DE (2012)
Daxweiler, DE (2011 - 2024)

Company Filing History:

9 out of 378

Bayer Pharma Aktiengesellschaft

patents

7 out of 12,157

Bayer Aktiengesellschaft

patents

3 out of 107

Merz Pharma Gmbh & Co Kgaa

patents

4. 1 out of 1

Beyer Aktiengesellschaft

patent

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12239630 - Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor (2025-03-04),

2. 12023319 - Carboxylic acid aromatic amides (2024-07-02),

3. 11905270 - Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor (2024-02-20),

4. 11319324 - Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors (2022-05-03),

5. 11149018 - Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof (2021-10-19),

6. 11142523 - 1,3-thiazol-2-yl substituted benzamides (2021-10-12),

7. 11136296 - Substituted-arylethyl-2-arylquinoline-4-carboxamides and use thereof (2021-10-05),

8. 10730856 - Benzimidazole derivatives as EP4 ligands (2020-08-04),

9. 10472354 - 1,3-thiazol-2-yl substituted benzamides (2019-11-12),

10. 10202369 - 1,3-thiazol-2-yl substituted benzamides (2019-02-12),

11. 10183937 - 1,3-thiazol-2-yl substituted benzamides (2019-01-22),

12. 10174016 - 1,3-thiazol-2-yl substituted benzamides (2019-01-08),

13. 10172814 - Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof (2019-01-08),

14. 9708311 - Benzimidazole derivatives as EP4 antagonists (2017-07-18),

15. 8288549 - Glycine B antagonist (2012-10-16),

Title: The Innovative Mind of Jens Nagel: A Trailblazer in Pharmaceutical Discoveries

Introduction: Jens Nagel, a visionary inventor from Daxweiler, Germany, has left an indelible mark in the field of pharmaceutical innovations with his groundbreaking research and numerous patents.

Latest Patents: Jens Nagel's recent patents showcase his pioneering work in the pharmaceutical domain. One of his latest inventions is the development of Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor, offering new possibilities in the treatment and prophylaxis of various diseases. Another notable patent is on Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors, focusing on the treatment of neurogenic diseases.

Career Highlights: With a total of 15 patents to his name, Jens Nagel has made significant contributions to the pharmaceutical industry. He has been associated with renowned companies such as Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft, where he has applied his inventive spirit to drive progress and innovation.

Collaborations: Throughout his career, Jens Nagel has collaborated with talented individuals such as Nico Bräuer and Andrea Rotgeri, fostering a culture of creativity and teamwork. These partnerships have led to the development of cutting-edge pharmaceutical solutions that have the potential to transform healthcare.

Conclusion: In conclusion, Jens Nagel's remarkable journey as an inventor underscores his unwavering commitment to pushing the boundaries of pharmaceutical research. His innovative patents and successful collaborations stand as a testament to his enduring legacy in the world of inventions.

This text is generated by artificial intelligence and may not be accurate.